Much of the Slitterhead gameplay revolves around Rarities, gifted humans who can achieve higher attunement with the mysterious Night Owl and maintain their consciousness while being possessed, which allows them to use some unique fighting styles and skills that can make your life easier against all sorts of opponents. Unlock new Rarities is also a necessity to proceed in the main campaign, as you will need the help of specific characters to continue Night Owl's war against Slitterheads. The first time this happens is right after starting to investigate a religious cult that seems to be bringing together monsters and […]
With one of the most fractious, ruthless, and discordant federal elections in living memory just around the corner, the politics across wide swathes of the U.S. remains hopelessly divided. Yet, judging each presidential candidate strictly on policy proposals represents one of the only few systematic methods of sifting through personal and groupthink biases, which in turn paves the way for decisions that are rational and grounded in facts. The tech sector constitutes an integral component of not just the market but the economy as a whole. Add in the escalation of Artificial Intelligence (AI) in nearly every domain, and tech […]
AMD's flagship "Strix Point" Ryzen AI 9 HX 370 has now been tested on One-Netbook's newest ONEXFLY F1 Pro handheld, revealing impressive performance for a compact device. ONEXFLY F1 Pro Becomes The First Handheld To Feature AMD's Ryzen AI 9 HX 370 APU, Bringing In High-End Gaming Performance AMD's "Ryzen AI 300" series has seen decent adoption from the laptop segment, given its impressive performance capabilities and AI computational power; however, in terms of the handheld market, the integration of Strix Point APUs has been a slowed one, especially with the flagship Ryzen AI 9 HX 370, since One-Netbook is […]
In Slitterhead, Hyoki and his Rarities will have to fight a variety of enemies of the supernatural kind, but there will be times when regular old humans will get in their way, leaving them no choice but to use their special powers to take them out and continue their hunt for the vicious Slitterheads. These humans, however, are very different from the Civilians that Hyoki can possess and will fight back with everything they got. During the Oppressive Force mission, you will encounter members of the S.P.E.U., a military unit out to destroy not only Slitterheads but also Hyoki. Dealing […]
From offering a viable solution to the obesity pandemic and its comorbidities to reducing the demand for ResMed's continuous Positive Airway Pressure (PAP) therapy devices that are used to treat the symptoms of sleep apnea, it is hardly surprising that GLP-1 drugs currently constitute one of Wall Street's biggest thematic investment ideas for the ongoing decade. Even so, researchers continue to discover new use-cases for these miracle drugs, with the latest such discovery centering on alcohol addiction control. A Primer On GLP-1 Drugs The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this […]
Novo Nordisk (NYSE: NVO) has added billions of dollars in market capitalization over the ongoing craze around the GLP-1 anti-obesity and anti-diabetes drugs. However, the Danish pharma giant's most recognizable weight loss drug, Wegovy, is increasingly looking like a stepping stone instead of the promised panacea for the obesity pandemic. For the benefit of those who might not be aware, the GLP-1 hormone plays an important role in suppressing hunger and regulating the production of insulin and glucose. After a meal, GLP-1 agonists raise the level of insulin, which decreases blood glucose levels. Simultaneously, these drugs reduce the speed at […]
There is a reason why biotech is considered a very volatile sector. After all, fortunes are made and destroyed within a few seconds in this sphere, dictated by the outcome of clinical trials for experimental therapies. Fortunately, over the past few days, we've received some very encouraging news on two unrelated but equally important vectors for improving the overall quality of human life: a new gene therapy that has the potential to significantly extend the human lifespan and a new oral GLP-1 weight loss drug candidate from Viking Therapeutics (NASDAQ: VKTX). Viking Therapeutics’ Oral GLP-1 Weight Loss Drug Is Out […]
The GLP-1 weight loss drug phenomenon has graduated from a largely theoretical solution to the obesity pandemic to a hardcore economic reality with real-world ramifications. Gone are the days when these drugs were posited as merely a single vector in dealing with the worldwide obesity crisis. Instead, the accelerating adoption of GLP-1 drugs is now giving rise to critical commercial tailwinds that are transforming entire economies. For the benefit of those who might not be aware, GLP-1 drugs can induce significant weight loss by suppressing hunger and regulating the production of insulin and glucose. Novo Nordisk uses Semaglutide as its […]
If you weren't already aware, GLP-1 weight loss drugs from the likes of Novo Nordisk and Eli Lilly and Company are the biotech sphere's new craze, managing to rope in seasoned analysts who appear to be salivating at the prospect of billions of dollars in additional revenue streams. Yet, the hype seems to have lost some of its patina recently. TD COWEN: “.. surprised to see two months in a row of declines in the number of people who describe themselves as current users of GLP-1s. .. We believe this is a function of capacity constraints .. Penetration rates may […]
The market for weight loss drugs is big enough to allow a plethora of competitors to thrive, as per the prevailing thesis. And we are not just talking about GLP-1 agonists from heavyweights such as Novo Nordisk and Eli Lilly and Company but also newer concoctions, including Amylin-based treatment that is being championed by Zealand. However, it is the unusual agility that is being demonstrated by the reigning Goliaths in this sphere that continues to limit the ascendancy of upstarts. As our regular readers would know, we maintain a generally positive view of weight loss treatments that leverage GLP-1 agonists. […]
Novo Nordisk is currently plowing billions of dollars into new facilities to satiate the rip-roaring demand for its GLP-1 cocktail Wegovy. Yet, a sizable supply-demand gap persists, prompting the pharma giant to flag the possibility of "supply disruptions" in the near term. To wit, Novo Nordisk has now announced via a supply update that it has resumed the shipments of 1.7 mg dose strength Wegovy GLP-1 cocktail in the US following a "short-term stock-out." Bear in mind that 1.7 and 2.4 mg dose strengths are primarily geared toward weight loss maintenance. However, the company chose to flag the potential for […]
One of the biggest hurdles to the mass appeal of a new class of GLP-1 weight loss drugs remains their sky-high prices. Insurance coverage, however, is playing a fundamental role in addressing these affordability concerns, with Eli Lilly and Company coming out today with important price updates for those with insurance coverage in the US. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. These drugs stimulate the release of insulin in the pancreas, block the unhelpful release of glucagon after meals to prevent excess glucose from entering the bloodstream, and slow gastric emptying to reduce […]
GLP-1 weight loss drugs and the ongoing advances in the AI sphere are currently two of the biggest thematic plays that Wall Street is relentlessly championing, facilitating a phenomenal influx of capital in companies that are seen as beneficiaries of the upheaval that the proponents of these nascent technologies argue is just around the proverbial corner. Recently, GLP-1 drugs from the likes of Novo Nordisk (NVO) and Eli Lilly and Company (LLY) have been billed as a blessing in disguise for the airline industry and a harbinger of doom for the fast food sector. Can a single drug really induce […]
With around $100 billion in annual sales by the end of this decade up for grabs, the GLP-1 drug war for the global waistline is heating up. Around two weeks back, Novo Nordisk created a media spectacle out of a study that claimed its GLP-1 weight loss drug could slash death risk from heart disease by up to 20 percent. This salvo was apparently fired in response to the steeply discounted price at which Eli Lilly and Company began marketing its own GLP-1 drug. Well, today, the American pharma giant is again attacking Novo Nordisk's proverbial front lines, resplendent in […]
A price war waged by big pharma usually works in the favor of consumers, in the short term at least, or until the victor captures the market and establishes a monopoly. Eli Lilly and Company unveiled its opening gambit earlier this week by pricing its GLP-1 weight loss drug at a substantial discount to a competing offering by Novo Nordisk. The Danish pharmaceutical giant has now responded by hyping up the results of a critical trial. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. This hormone forms the bedrock of Novo Nordisk's Ozempic and Wegovy […]
DDR5 Gear 2 performs better than Gear 4 memory settings in both latency and performance departments on Intel Z890 motherboards. High memory frequency with DDR5 CUDIMM on Intel and AMD platforms doesn't favor performance or latency In recent weeks, we have seen a plethora of CUDIMMs being launched. Corsair, G.Skill, Colorful, and many more manufacturers introduced their own CUDIMM DDR5 memories for Intel's Z890 and AMD X870/X870E platforms that seek to enhance the overall performance of the system. Some overclockers already broke world records by breaking the 10000 MT/s and 12000 MT/s marks, but as we said previously, we are […]
Apple has recently announced the new M4 MacBook Pro models along with an upgraded iMac and a redesigned Mac mini. While the devices are pretty capable in terms of processing power, the company saw fit to keep the design language the same as previous models. The design is not bad, per se, but it has been running for the past few years. A prominent analyst now claims that Apple is working to introduce a redesigned MacBook Pro in 2026 with an OLED display, which will replace the mini-LED display on the current models. Apple's 2026 MacBook Pro models will feature […]
From offering a viable solution to the obesity pandemic and its comorbidities to reducing the demand for ResMed's continuous Positive Airway Pressure (PAP) therapy devices that are used to treat the symptoms of sleep apnea, it is hardly surprising that GLP-1 drugs currently constitute one of Wall Street's biggest thematic investment ideas for the ongoing decade. Even so, researchers continue to discover new use-cases for these miracle drugs, with the latest such discovery centering on alcohol addiction control. A Primer On GLP-1 Drugs The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this […]
Novo Nordisk (NYSE: NVO) has added billions of dollars in market capitalization over the ongoing craze around the GLP-1 anti-obesity and anti-diabetes drugs. However, the Danish pharma giant's most recognizable weight loss drug, Wegovy, is increasingly looking like a stepping stone instead of the promised panacea for the obesity pandemic. For the benefit of those who might not be aware, the GLP-1 hormone plays an important role in suppressing hunger and regulating the production of insulin and glucose. After a meal, GLP-1 agonists raise the level of insulin, which decreases blood glucose levels. Simultaneously, these drugs reduce the speed at […]
There is a reason why biotech is considered a very volatile sector. After all, fortunes are made and destroyed within a few seconds in this sphere, dictated by the outcome of clinical trials for experimental therapies. Fortunately, over the past few days, we've received some very encouraging news on two unrelated but equally important vectors for improving the overall quality of human life: a new gene therapy that has the potential to significantly extend the human lifespan and a new oral GLP-1 weight loss drug candidate from Viking Therapeutics (NASDAQ: VKTX). Viking Therapeutics’ Oral GLP-1 Weight Loss Drug Is Out […]
The GLP-1 weight loss drug phenomenon has graduated from a largely theoretical solution to the obesity pandemic to a hardcore economic reality with real-world ramifications. Gone are the days when these drugs were posited as merely a single vector in dealing with the worldwide obesity crisis. Instead, the accelerating adoption of GLP-1 drugs is now giving rise to critical commercial tailwinds that are transforming entire economies. For the benefit of those who might not be aware, GLP-1 drugs can induce significant weight loss by suppressing hunger and regulating the production of insulin and glucose. Novo Nordisk uses Semaglutide as its […]
If you weren't already aware, GLP-1 weight loss drugs from the likes of Novo Nordisk and Eli Lilly and Company are the biotech sphere's new craze, managing to rope in seasoned analysts who appear to be salivating at the prospect of billions of dollars in additional revenue streams. Yet, the hype seems to have lost some of its patina recently. TD COWEN: “.. surprised to see two months in a row of declines in the number of people who describe themselves as current users of GLP-1s. .. We believe this is a function of capacity constraints .. Penetration rates may […]
The market for weight loss drugs is big enough to allow a plethora of competitors to thrive, as per the prevailing thesis. And we are not just talking about GLP-1 agonists from heavyweights such as Novo Nordisk and Eli Lilly and Company but also newer concoctions, including Amylin-based treatment that is being championed by Zealand. However, it is the unusual agility that is being demonstrated by the reigning Goliaths in this sphere that continues to limit the ascendancy of upstarts. As our regular readers would know, we maintain a generally positive view of weight loss treatments that leverage GLP-1 agonists. […]
Novo Nordisk is currently plowing billions of dollars into new facilities to satiate the rip-roaring demand for its GLP-1 cocktail Wegovy. Yet, a sizable supply-demand gap persists, prompting the pharma giant to flag the possibility of "supply disruptions" in the near term. To wit, Novo Nordisk has now announced via a supply update that it has resumed the shipments of 1.7 mg dose strength Wegovy GLP-1 cocktail in the US following a "short-term stock-out." Bear in mind that 1.7 and 2.4 mg dose strengths are primarily geared toward weight loss maintenance. However, the company chose to flag the potential for […]
One of the biggest hurdles to the mass appeal of a new class of GLP-1 weight loss drugs remains their sky-high prices. Insurance coverage, however, is playing a fundamental role in addressing these affordability concerns, with Eli Lilly and Company coming out today with important price updates for those with insurance coverage in the US. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. These drugs stimulate the release of insulin in the pancreas, block the unhelpful release of glucagon after meals to prevent excess glucose from entering the bloodstream, and slow gastric emptying to reduce […]
GLP-1 weight loss drugs and the ongoing advances in the AI sphere are currently two of the biggest thematic plays that Wall Street is relentlessly championing, facilitating a phenomenal influx of capital in companies that are seen as beneficiaries of the upheaval that the proponents of these nascent technologies argue is just around the proverbial corner. Recently, GLP-1 drugs from the likes of Novo Nordisk (NVO) and Eli Lilly and Company (LLY) have been billed as a blessing in disguise for the airline industry and a harbinger of doom for the fast food sector. Can a single drug really induce […]
With around $100 billion in annual sales by the end of this decade up for grabs, the GLP-1 drug war for the global waistline is heating up. Around two weeks back, Novo Nordisk created a media spectacle out of a study that claimed its GLP-1 weight loss drug could slash death risk from heart disease by up to 20 percent. This salvo was apparently fired in response to the steeply discounted price at which Eli Lilly and Company began marketing its own GLP-1 drug. Well, today, the American pharma giant is again attacking Novo Nordisk's proverbial front lines, resplendent in […]
A price war waged by big pharma usually works in the favor of consumers, in the short term at least, or until the victor captures the market and establishes a monopoly. Eli Lilly and Company unveiled its opening gambit earlier this week by pricing its GLP-1 weight loss drug at a substantial discount to a competing offering by Novo Nordisk. The Danish pharmaceutical giant has now responded by hyping up the results of a critical trial. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. This hormone forms the bedrock of Novo Nordisk's Ozempic and Wegovy […]